Drugs / Isradipine
Isradipine
also known as
Dynacirc · Dynacirc CR · ISR · Isradipino · Isrodipine · NSC-759892 · PN 200-110 · Prescal
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DYNACIRC | — | 1990-12-20 | fda.gov ↗ |
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03083353 | Jan 2020 → Jun 2023 | nicotine dependence | Jasper A. Smits | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT00733239 | Aug 2008 → Oct 2010 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00593463 | Sep 2006 → May 2010 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01895270 | Oct 2013 → Apr 2016 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01784666 | Feb 2013 → Apr 2014 | bipolar disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00753636 | Apr 2008 → Jun 2009 | Parkinson disease | Northwestern University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01658150 | Sep 2012 → Jan 2018 | schizoaffective disorder, schizophrenia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT02136823 | Jun 2009 → May 2015 | spinal cord injury | Shirley Ryan AbilityLab | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00909545 Comparator | Jul 2009 → Dec 2011 | Parkinson disease | Northwestern University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01007994 Comparator | Nov 2009 → Jan 2020 | secondary hypertension | Northwell Health | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02168842 Comparator | Nov 2014 → Nov 2018 | Parkinson disease | University of Rochester | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isradipine | “amlodipine, felodipine, isradipine, nicardipine, nifedipine” NCT00684489 ↗ |
| Known as | Dynacirc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1648 ↗ |
| Known as | Dynacirc CR | “Dynacirc CR (Isradipine)” NCT00753636 ↗ |
| Known as | ISR | “L-type calcium-channel blocker isradipine (ISR)” PMID 33281447 ↗ Nov 2020 |
| Known as | Isradipino | ChEMBL registry synonym — accepted as the source's own label CHEMBL1648 ↗ |
| Known as | Isrodipine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1648 ↗ |
| Known as | NSC-759892 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1648 ↗ |
| Known as | PN 200-110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1648 ↗ |
| Known as | Prescal | ChEMBL registry synonym — accepted as the source's own label CHEMBL1648 ↗ |
| Action | Inhibit | “acts by blocking a specific type of receptor in the brain called a calcium channel” NCT01658150 ↗ |
| Modality | Small molecule | “Isradipine is a dihydropyridine calcium channel inhibitor” PMID 33460320 ↗ Jan 2021 |
| Route | Oral | “10 mg oral capsule” NCT00593463 ↗ |